PALATIN TECHNOLOGIES INC
PTNDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PTN Earnings Report
FQ end 2026-06
How PTN's past catalysts played out
Bremelanotide
Kidney Disease
tirzepatide
Obesity
PL3994
Hypertension
PL8177
Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bremelanotide | Phase 3 | Kidney Disease | - | - |
tirzepatide | Phase 2 | Obesity | - | - |
PL3994 | Phase 2 | Hypertension | - | - |
PL8177 | Phase 2 | Ulcerative Colitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PALATIN TECHNOLOGIES INC's drug pipeline?→
CatalystAlert tracks 4 drug candidates in PALATIN TECHNOLOGIES INC's (PTN) pipeline across Phase 3, Phase 2. Its lead program is Bremelanotide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PALATIN TECHNOLOGIES INC's next FDA catalyst?→
PALATIN TECHNOLOGIES INC's (PTN) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PTN biotech catalysts?→
Add PTN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PALATIN TECHNOLOGIES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.